- Open Access
Activin-A up-regulates type I activin receptor mRNA levels in human immortalized extravillous trophoblast cells.
Reproductive Biology and Endocrinology volume 1, Article number: 29 (2003)
Activin is known to play an important regulatory role in reproduction, including pregnancy. To further examine the role and signaling mechanism of activin in regulating placental function, the steady-state level of activin type I receptor (ActRI) mRNA in immortalized extravillous trophoblasts (IEVT) cells was measured using competitive PCR (cPCR). An internal standard of ActRI cDNA for cPCR was constructed for the quantification of ActRI mRNA levels in IEVT cells. ActRI mRNA levels were increased in a dose-dependent manner by activin-A with the maximal effect observed at the dose of 10 ng/ml. Time course studies revealed that activin-A had maximal effects on ActRI mRNA levels at 6 hours after treatment. The effects of activin-A on ActRI mRNA levels was blocked by follistatin, an activin binding protein, in a dose-dependent manner. In addition, inhibin-A inhibited basal, as well as activin-A-induced ActRI mRNA levels. These findings provide evidence, for the first time, that activin-A modulates ActRI mRNA levels in human trophoblast cells.
Although activins and inhibins were originally isolated from follicular fluids and identified as stimulators and inhibitors, respectively, of pituitary follicle-stimulating hormone (FSH), the identification of inhibins and activins in a wide variety of tissues suggest that these factors play much greater roles than the control of FSH secretion [1–5]. Also, it has become evident that these factors exert their effects mostly in autocrine/paracrine manners.
Similar to other members of the transforming growth factor-β (TGF-β) family, activins exert their actions by interacting with both type I and type II membrane serine/threonine kinase receptors [6, 7]. Two type I (ActRI and ActRIB) and two type II (ActRII and ActRIIB) receptors have been shown to interact with activins  and their mRNAs have been detected in human placental trophoblast cells [8–10], as well as in choriocarcinoma cells . Activins, particularly activin-A, has been shown to be produced by human placenta [5, 11–13]. Many studies have demonstrated that activin-A plays important regulatory roles in human placenta, including stimulation of cytotrophoblast differentiation into invasive extravillous cytotrophoblast ; stimulation of progesterone [11, 14–16], human chorionic gonadotropin (hCG)[15, 17, 18], estradiol , gonadotropin-releasing hormone (GnRH)  and oxytocin  secretion. However, regulation of activin signaling at the receptor level has not been examined.
The human placenta provides specialized functions during gestation that is critical for the development of the embryo and fetus. Among these important functions are the production of hormones, cytokines and growth factors that contribute to the gestational coordination of maternal, extraembryonic, and embryonic tissues. Development of the human placenta depends on proliferation and differentiation of certain trophoblast cells as well as invasion to the endometrium and its vasculature by a highly proliferative, migratory and invasive subpopulation of extravillous trophoblast (EVT) cells .
To further study activin signaling in human placenta, we have developed a competitive quantitative PCR to measure ActRI mRNA levels in an immortalized EVT cell line, HTR8/SVneo. We report here the first evidence that activin-A regulates its own receptor mRNA levels in a dose- and time-dependent manner and this effect can be blocked by its binding protein, follistatin, or its antagonist, inhibin-A in human placenta.
Materials and Methods
The use of placental tissue samples and cell lines was approved by the Clinical Screening Committee for Research and Other Studies Involving Human Subjects, University of British Columbia. The HTR-8/SVneo trophoblast cell line was generously provided by Dr. PK Lala (University of Western Ontario). This cell line was obtained from human first trimester placenta explant cultures and immortalized using SV40 large T antigen . Cells were cultured in RPMI 1640 medium containing 10% FBS and antibiotics (Invitrogen Canada Inc., Burlinton, ON) as previously described .
Oligonucleotide primers were synthesized based on the published sequences of the human ActRI , and β-actin . The upstream primer (ActRI-1), 5'-GATGAGAAGTCATGGTTCAGG-3', and downstream primer (ActRI-2), 5'-TATGTTTGGCCTTTGTTGATC-3' were designed such that the predicted sizes of PCR products are 700 bp for native ActRI cDNA. Primers are chosen to flank introns so that the amplified ActRI cDNA is readily distinguished from a possible contaminating genomic DNA. Another pair of primers, ActRI-3 (5'-GATGAGAAGTCATGGTTCAG G-3') and ActRI-4 (5'-TATGTTTGGCCTTTGTTGATC-3") were synthesized and used as nested primers to validate the internal standard and measuring the regulation of ActRI mRNA levels in HTR8/SVneo cells. The human β-actin primers, used as another internal control to normalize cDNA amount in different samples, are AC1 upstream and AC2 downstream primers of which sequence are 5'-GGACCTGACTGACTACCTCATGAA-3' and 5'-GGTGGAAGGTGGTCAACACCTAG-3', respectively.
Human recombinant activin-A, inhibin-A and follistatin-288 were kindly provided by Dr. Parlow at the National Hormone and Pituitary Program. The HTR8/SVneo cells were plated in 24-well culture plates in FBS supplemented RPMI medium. Two days after plating when cells reach about 70% confluence, the culture medium was replaced with serum-free RPMI 1640. For dose-response studies, cells were treated with various doses (0.1 to 30 ng/ml) of activin-A for 12 hours. For time-course experiments, cells were cultured in the presence or absence of 10 ng/ml activin-A for 1, 3, 6, 12, 24 hours. To determine the interaction between activin and follistatin, cells were treated with activin-A (10 ng/ml) alone, or activin-A with different concentrations of follistatin-288 (10, 20, 50, or 100 ng/ml) for 6 h. Similarly, to examine the effect of inhibin on basal and activin-A-stimulated ActRI mRNA levels, cells were treated with Activin-A, inhibin-A, either alone or in combination for 6 h. There are four wells in each treatment group and each experiment was conducted three times.
Construction of an internal standard for comparative PCR
Cloning of native ActRI PCR product using primers ActRI-1 and ActRI-2 was performed by ligating the PCR product into a pDirect (BD Biosciences Clontech, Palo Alto, CA), followed by sequencing analysis to confirm the identity. To construct an internal standard for comparative PCR, a 156 base pair segment was removed from the cloned native ActRI PCR product by restriction digestion using StyI and Eco47III (Fig. 1). With the same pair of primers is used in PCR, the subcloned mutant ActRI template yielded a PCR product 156 base pairs smaller than that from the native cDNA template.
Total RNA extraction, Reverse transcription and Competitive PCR
Total RNA from HTR-8/SVneo cells was extracted using the RNaid Kit (Bio/Can Scientific Inc., Mississauga, ON) following manufacture's suggested procedures. Two μg of total RNA was used to synthesized cDNA using First Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech Inc., Oakville, ON) as previously described . cPCR is similar to PCR except that it includes an internal standard to monitor the variation between different tubes as well as among different experiments. In the cPCR reaction, target sequences of native cDNA or sample cDNA combined with 0.5 pg/μl of the internal standard of ActRI cDNA (internal standard, IS) are co-amplified in a tube with a volume of 50 μl containing 5 μl of 10 × PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl], 1.5 μl MgCl2 (50 mM), 1 μl dNTPs (10 mM), 0.5 μl Taq DNA polymerase (5 units/μl) (Gibco BRL), 38 μl sterile Milli-Q water, 1 μl each (5 μM) of specific primers (ActRI-3 and ActRI-4) and equal volume (1 μl) of IS and cDNA sample or native cDNA. PCR amplifications were performed for 35 cycles in a Perkin-Elmer/Citus DNA thermal cycler with denaturation at 94°C for 30 seconds, annealing at 53°C for 30 seconds and extension at 72°C for 90 seconds. The final cycle was followed by a 15 minutes extension step at 72°C. PCR for β-actin was conducted for 25 cycles using similar conditions as described for ActRI expect that 2 μl of cDNA samples were used and annealing temperature was 55°C.
Assessment and quantification of ActRI mRNA levels
After cPCR, 10 μl from each PCR reaction was subjected to gel electrophoresis and recorded with a negative film. The intensity of PCR products was determined using a densitometer and expressed as the ratio of ActRI and IS. β-actin mRNA levels were used to normalize the samples for variation in cDNA concentrations. Statistical significance of the data was determined by one-way analysis of variance followed by Scheffe's test. p < 0.05 was considered significant.
Validation of cPCR
To validate the cPCR for measurement of ActRI mRNA levels, PCR was conducted using a constant amount of IS (0.5 pg) and an increasing amount of native ActRI cDNA (0.01, 0.1, 1, 10 pg). As shown in Fig. 2A, the ratio of band intensity (native ActRI cDNA/IS), measured by densitometry scanning, was nearly linear when plotted as a function of the amount of native ActRI cDNA in the cPCR reaction. To control for variation in sample cDNA concentrations, β-actin mRNA levels in each sample was also measured and used to normalize the ActRI mRNA levels. To validate a semi-quantitative PCR for β-actin, PCR was first conducted for 20 to 40 cycles. There is a linear relationship between the amount of PCR product generated and the number of PCR cycle when PCR was conducted between 20 to 30 cycles (data not shown) and therefore, subsequent β-actin PCR was conducted for 25 cycles. In addition, when different amount of cDNA (from 0.5 to 4 μl) was used in PCR, there is a linear relationship between the amount of initial cDNA and PCR product (Fig. 2B).
Activin-A stimulated ActRI mRNA expression
The ActRI mRNA level, measured at 12 hours after treatment, was increased in a dose-dependent manner by activin-A (Fig. 3). A significant stimulation (P < 0.05) of ActRI mRNA levels was observed at the dose of 3, 10 and 30 ng/ml. When IEVT cells were treated with activin-A (10 ng/ml) for different period of time, a significant increase in ActRI mRNA level was found at 3 hours (P < 0.05) and the maximal response observed at 6 hours (P < 0.01) after treatment. By 24 h after treatment, ActRI mRNA levels in activin-A treated cells were not significantly different from those in the control cells (Fig. 4).
Follistatin blocked the effect of activin-A on ActRI mRNA expression
The activin-binding protein, follistatin, has been shown to neutralize the effects of activin in several biological systems [24–27]. To determine the specificity of activin-A action, we examined the effects of increasing concentrations of recombinant human follistatin-288 on activin-A-induced ActRI mRNA levels. Treatment with activin-A alone resulted in a significant increase in ActRI mRNA levels (P < 0.05); however, when activin-A and follistatin were added to the culture together, the activin-A-stimulated ActRI mRNA levels were decreased. At the doses of 50 and 100 ng/ml, follistatin-288 completely blocked the effects of activin-A on the ActRI mRNA levels (Fig. 5).
Inhibin-A antagonized the effect of activin-A on ActRI mRNA expression
Inhibin-A has opposing effects as activin-A in many biological systems. In this study, we also examined the effect of inhibin-A on ActRI mRNA levels. Inhibin-A (10 ng/ml) induced a 60% reduction in ActRI mRNA levels (p < 0.01) within six hours of treatment. When inhibin-A was applied together with activin-A (10 ng/ml), significant reductions in activin-A-stimulated ActRI mRNA levels were observed (Fig. 6).
For many years the placental cytotrophoblasts obtained by disaggregation of placental tissue have served as the most widely investigated model for the study of placental function in vitro. However, the purity of cytotrophoblasts was not consistent. The IEVT cells used in the study exhibit similar cellular function to normal EVT cells  and they provide a promising model to study the function of EVT cells. Using these cells, we have demonstrated that activin-A stimulates, while inhibin-A inhibits, ActRI mRNA levels.
Our results showed that ActRI mRNA accumulation at 12 hours after treatment was stimulated in a dose-dependent manner by activin-A. The time course of the activin-A effect on ActRI mRNA showed responses at 3 to 12 hours after treatment, with a maximal increase occurring at 6 hours. This response pattern of activin-A on ActRI mRNA suggests that activin-A exerts a positive feedback effect on its own receptor and that the action of activin-A on ActRI mRNA level is transient. The transient effect of activin-A is likely due to the termination of activin signaling. Activin signaling has been shown to be terminated by negative feedback mechanisms involving the activation of Smad7 by activin, and in turn, Smad7 inhibits further activin signaling by blocking the phosphorylation of Smad2/3 by activin type I receptors [28, 29]. In addition, activin signaling can also be terminated by the degradation of Smad proteins through the ubiquitination pathway .
The changes in ActRI mRNA levels as determined by cPCR in this study could have resulted from changes in the transcriptional rate of ActRI gene and/or the stability of the ActRI mRNA. Activin is known to regulate gene expression at the level of transcription via the Smad signaling pathway [5–7] and expression of Smads in trophoblast cells including the HTR8/SVsno have been demonstrated [31, 32], it is therefore possible that activin-A may regulate its receptor expression at the level of gene transcription. Future studies are also needed to confirm that there is a correlated change at the protein level.
Although this is the first study demonstrating that activin-A regulates its own receptor expression in human placenta, several studies in other tissues have also observed modulation of activin signaling by activin itself. In the rat pituitary, activin-A stimulated ActRI and ActRIIB mRNA levels without altering ActRII mRNA expression . On the other hand, activin-A downregulated ActRIB, ActRII and ActRIIB mRNA levels in a cell line derived from a p53(-/-)inhibin-α (-/-) mouse testicular tumor .
Follistatin is widely distributed and produced by many activin-responsive tissues [1, 25] and may, therefore, serve to anatomically and temporally limit the local activities of activin. Follistatin mRNA transcripts and immunoreactivities have been detected in placental trophoblast cells  Similar to many other systems [24, 25], follistatin also neutralizes activin actions in human placenta . In the present study, we also found that the stimulatory effect of activin-A on ActRI mRNA levels could be completely blocked by follistatin. Since it is known that follistatin inhibits activin actions by binding to activin and thus preventing the interaction between activin and its type II receptor  the neutralization of activin-A action on ActRI mRNA levels by follistatin suggests that the action of activin is a receptor-mediated event.
Inhibin and activin possess opposing activities in several biological systems including pituitary FSH secretion, erythroid differentiation, and gonadal sex-steroid production . In the present study, we found that inhibin-A caused a 60 % reduction in basal ActRI mRNA levels and completely inhibited activin-A-induced ActRI mRNA expression. This finding is in agreement with the observation that inhibin counteracts the effects of activin on cultured first trimester trophoblast cells .
In summary, we have demonstrated that in activin-A upregulates mRNA levels of it own receptor ActRI in human extravillous trophoblast cells. Since activin-A has been shown to stimulate the differentiation of extravillous trophoblast cells , the up-regulation of ActRI by activin-A suggests a positive feedback regulatory mechanism by which activin-A modulates its own signaling in these cells.
DePaolo LV, Bicsak A, Erickson GF, Shimasaki S, Ling N: Follistatin and activin: a potential intrinsic regulatory system within diverse tissues. Proc Soc Exp Biol Med. 1991, 18: 500-512.
Bilezikjian LM, Vale WW: Local extragonadal roles of activins. Trends Endocrinol Metab. 1992, 3: 218-223.
Mather JP, Woodruff TK, Krummen LA: Paracrine regulation of reproductive function by inhibin and activin. Proc Soc Exp Biol Med. 1992, 201: 1-15.
Mather JP, Moore A, Li RH: Activins, inhibins, and follistatins: further thoughts on a growing family of regulators. Proc Soc Exp Biol Med. 1997, 215: 209-222.
Peng C, Mukai ST: Activins and their receptors in female reproduction. Biochem Cell Biol. 2000, 78: 261-279. 10.1139/bcb-78-3-261.
Massagué J: TGF-β signal transduction. Annu Rev Biochem. 1998, 67: 753-791. 10.1146/annurev.biochem.67.1.753.
Roberts AB: TGF-β signaling from receptors to the nucleus. Microbes Infect. 1999, 1: 1265-1273. 10.1016/S1286-4579(99)00258-0.
Peng C, Huang THJ, Jeung EB, Donaldson CJ, Vale WW, Leung PCK: Expression of the Type II activin receptor gene in the human placenta. Endocrinology. 1993, 133: 3046-3049.
Peng C, Ohno T, Koh LY, Chen VT, Leung PCK: Human ovary and placenta express messenger RNA for multiple activin receptors. Life Sci. 1999, 64: 983-994. 10.1016/S0024-3205(99)00035-1.
Shinozaki H, Minegishi T, Nakamura K, Tano M, Miyamoto K, Ibuki Y: Type II and type IIB activin receptors in human placenta. Life Sci. 1995, 56: 1699-1706. 10.1016/0024-3205(95)98576-2.
Ni X, Luo S, Minegishi T, Peng C: Activin A in JEG-3 cells: potential role as an autocrine regulator of steroidogenesis in humans. Biol Reprod. 2000, 62: 1224-1230.
Petraglia F, Gallinelli A, De Vita D, Lewis K, Mather L, Vale W: Activin at parturition: changes of maternal serum levels and evidence for binding sites in placenta and fetal membranes. Obstet Gynecol. 1994, 84: 278-282.
Qu J, Thomas K: Inhibin and activin production in human placenta. Endocrine Rev. 1995, 16: 485-507.
Caniggia I, Lye SJ, Cross JC: Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology. 1997, 138: 3976-3986.
Petraglia F, Vaughan J, Vale W: Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. Proc Natl Acad Sci USA. 1989, 86: 5114-5117.
Petraglia F, Gallinelli A, Grande A, Florio P, Ferrari S, Genazzani AR, Ling N, DePaolo LV: Local production and action of follistatin in human placenta. J Clin Endocrinol Metab. 1994, 78: 205-210.
Steele GL, Currie WD, Ho Yuen B, Jia XC, Perlas E, PCK Leung: Acute stimulation of human chorionic gonadotropin secretion by recombinant human activin-A in first trimester human trophoblast. Endocrinology. 1993, 133: 297-303.
Song Y, Keelan J, France JT: Activin-A stimulates, while transforming growth factor beta 1 inhibits, chorionic gonadotrophin production and aromatase activity in cultured human placental trophoblasts. Placenta. 1996, 17: 603-610.
Florio P, Lombardo M, Gallo R, Di Carlo C, Sutton S, Genazzani AR, Petraglia F: Activin A, corticotropin-releasing factor and prostaglandin F2α increase immunoreactive oxytocin release from cultured human placental cells. Placenta. 1996, 17: 307-311.
Morrish DW, Dakour J, Li H: Functional regulation of human trophoblast differentiation. J Reprod Immunol. 1998, 39: 179-195. 10.1016/S0165-0378(98)00021-7.
Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, Lala PK: Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res. 1993, 206: 204-211. 10.1006/excr.1993.1139.
Matsuzaki K, Xu J, Wang F, McKeeha WL, Krummen L, Kan M: A widely expressed transmembrane serine/threonine kinase that does not bind activin, inhibin, transforming growth factor β, or bone morphogenic factor. J Biol Chem. 1993, 268: 12719-12723.
Ng SY, Gunning P, Eddy R, Ponte P, Leavitt J, Shows T, Kedes L: Evolution of the functional human β-actin gene and its multipseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol. 1985, 5: 2720-2732.
Cataldo NA, Rabinovici J, Fujimoto VY, Jaffe B: Follistatin antagonizes the effects of activin-A on steroidogenesis in human luteinizing granulosa cells. J Clin Endocrinol Metab. 1994, 79: 272-277.
Michel U, Farnworth P, Findlay J: Follistatins: more than follicle-stimulating hormone suppressing proteins. Mol Cell Endocrinol. 1993, 91: 1-11. 10.1016/0303-7207(93)90248-I.
Shimonaka M, Inouye S, Shimasaki S, Ling N: Follistatin binds to both activin and inhibin through the common subunit. Endocrinology. 1991, 128: 3313-3316.
Shukovski L, Findlay JK, Robertson DM: The effect of follicle-stimulating hormone-suppressing protein or follistatin on luteinizing bovine granulosa cells in vitro and its antagonistic effect on the action of activin. Endocrinolology. 1991, 129: 3395-3402.
Nagarajan RP, Zhang J, Li W, Chen Y: Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem. 1999, 274: 33412-33418. 10.1074/jbc.274.47.33412.
Liu X, Nagarajan RP, Vale W, Chen Y: Phosphorylation regulation of the interaction between Smad7 and activin type I receptor. FEBS Lett. 2002, 519: 93-98. 10.1016/S0014-5793(02)02718-7.
Massagué J, Chen Y-G: Controlling TGF-β signaling. Gene Dev. 2000, 14: 627-644.
Wu D, Luo S, Wang Y, Zhuang L, Chen Y, Peng C: Smads in human trophoblast cells: expression, regulation and role in TGF-β-induced transcriptional activity. Mol Cell Endocrinol. 2001, 175: 111-121. 10.1016/S0303-7207(01)00397-5.
Xu G, Chakraborty C, Lala PK: Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells. Biochem Biophys Res Commun. 2001, 287: 47-55. 10.1006/bbrc.2001.5533.
Dalkin AC, Haisenleder DJ, Yasin M, Gilrain JT, Marshall JC: Pituitary activin receptor subtypes and follistatin gene expression in female rats: Differential regulation by activin and follistatin. Endocrinolology. 1996, 37: 548-554.
Di Simone N, Hall HA, Welt C, Schneyer AL: Activin regulates β A-subunit and activin receptor messenger ribonucleic acid and cellular proliferation in activin- responsive testicular tumor cells. Endocrinology. 1998, 139: 1147-1155.
de Winter J, ten Dijke P, de Vries CJM, van Achterberg TAE, Sugino H, de Waele P, Huylebroeck D, Verschueren K, Eijnden-van Raaij AJM: Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Mol Cell Endocrinol. 1996, 116: 105-114. 10.1016/0303-7207(95)03705-5.
This research was supported by grants from the Canadian Institutes of Health Research to PCKL and CP. PCKL is a Distinguished Scholar of the Michael Smith Foundation for Health Research. We thank NHPP and Dr. Parlow for providing recombinant human activin-A, inhibin-A and follistatin-288.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
About this article
Cite this article
Chen, V.T., Peng, C. & Leung, P.C. Activin-A up-regulates type I activin receptor mRNA levels in human immortalized extravillous trophoblast cells.. Reprod Biol Endocrinol 1, 29 (2003). https://doi.org/10.1186/1477-7827-1-29
- Activin Receptor
- Immortalized Extravillous Trophoblast Cells
- Competitive PCR